Asset Details
Do you wish to reserve the book?
Impact of Sarcopenia on Outcomes Following Intra-arterial Therapy of Hepatic Malignancies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Impact of Sarcopenia on Outcomes Following Intra-arterial Therapy of Hepatic Malignancies
Do you wish to request the book?
Impact of Sarcopenia on Outcomes Following Intra-arterial Therapy of Hepatic Malignancies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Impact of Sarcopenia on Outcomes Following Intra-arterial Therapy of Hepatic Malignancies
2013
Overview
Background
Assessment of patient performance status is often subjective. Sarcopenia—measurement of muscle wasting—may be a more objective means to assess performance status and therefore mortality risk following intra-arterial therapy (IAT).
Methods
Total psoas area (TPA) was measured on cross-sectional imaging in 216 patients undergoing IAT of hepatic malignancies between 2002 and 2012. Sarcopenia was defined as TPA in the lowest sex-specific quartile. Impact of sarcopenia was assessed relative to other clinicopathological factors.
Results
Indications for IAT included hepatocellular carcinoma (51 %), intrahepatic cholangiocarcinoma (13 %), colorectal liver metastasis (7 %), or other metastatic disease (30 %). Median TPA among men (568 mm
2
/m
2
) was greater than women (413 mm
2
/m
2
). IAT involved conventional chemoembolization (54 %), drug-eluting beads (40 %), or yttrium-90 (6 %). Median tumor size was 5.8 cm; most patients had multiple lesions (74 %). Ninety-day mortality was 9.3 %; 3-year survival was 39 %. Factors associated with risk of death were tumor size (HR = 1.84) and Child's score (HR = 2.15) (all
P
< 0.05). On multivariate analysis, sarcopenia remained independently associated with increased risk of death (lowest vs. highest TPA quartile, HR = 1.84;
P
= 0.04). Sarcopenic patients had a 3-year survival of 28 vs. 44 % for non-sarcopenic patients.
Conclusions
Sarcopenia was an independent predictor of mortality following IAT with sarcopenic patients having a twofold increased risk of death. Sarcopenia is an objective measure of frailty that can help clinical decision-making regarding IAT for hepatic malignancies.
Publisher
Springer US,Springer Nature B.V
Subject
/ Carcinoma, Hepatocellular - mortality
/ Chemoembolization, Therapeutic
/ Cholangiocarcinoma - complications
/ Cholangiocarcinoma - mortality
/ Cholangiocarcinoma - pathology
/ Colorectal Neoplasms - pathology
/ Frailty
/ Humans
/ Liver Neoplasms - complications
/ Liver Neoplasms - drug therapy
/ Male
/ Medicine
/ Oncology
/ Patients
/ Surgery
